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The humanised HMFG-1 immunoglobulin has been extensively developed as a clinical immunotherapeutic agent for MUC1
expressing tumours. We have constructed a single-chain Fv (scFv) and Fab fragment from this antibody and shown that both these
species retain their specificity for MUC1. The scFv was less stable and less soluble than the Fab. Detailed analyses of the binding
kinetics of the whole IgG and Fab fragment show that the affinity for MUC1 synthetic peptides is low (approximately 100nM for the
IgG and 10mM for the Fab), with particularly low but similar dissociation rate constants (0.031–0.095s
 1). Binding to native antigen
on the cell surface is over two orders of magnitude better. Confocal immunofluorescence microscopy shows that both the IgG and
Fab are internalised rapidly (the IgG is internalised within 15min) and colocalise to early endosomes. This work provides an
appreciation of the binding, internalising and trafficking kinetics, important for the development of future therapeutics based on this
antibody.
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Mucins are a family of glycoproteins expressed on the apical
surface of most epithelial cells. Their structural composition offers
cell surface protection and the homeostasis of the local molecular
microenvironment. Transmembrane mucins may function as cell
surface receptors conducting signals leading to responses such as
proliferation or apoptosis, whereas secreted mucins are predomi-
nantly implicated as a first line of defence for the epithelial surface
(reviewed in Hollingsworth and Swanson, 2004).
Mucins are comparatively large glycoproteins with molecular
weights of over 1000kDa and a biochemical composition of 50–
80% O-linked oligosaccharides. The major features of mucins are
the tandem repeat domains, sets of repeated amino-acid sequences
rich in serine, threonine and proline. In the case of MUC1, each
repeat unit typically consists of between 20 and 30 amino acids,
with up to 500 repeats per polymorphic mucin molecule (Gendler
et al, 1990).
The most well characterised mucin is MUC1 a type 1
transmembrane protein with the 20 amino-acid tandem repeat
sequence ‘PDTRPAPGSTAPPAHGVTSA’ (Burchell et al, 1989), an
SEA domain (which associates with lipid rafts) and a short C-
terminal cytoplasmic tail of 72 amino acids. The cytoplasmic tail,
which is highly conserved between species, contains seven tyrosine
residues, four of which lie in signalling pathway motifs (Zrihan-
Licht et al, 1994). Chimeric receptor studies have identified which
of these tyrosine residues are phosphorylated upon ligand binding
(Wang et al, 2003), but the exact nature of the true ligand is as yet
unknown. The cytoplasmic tail has also been shown to bind and
signal through b-catenin and the mitogen-activated kinase path-
ways (Yamamoto et al, 1997; Schroeder et al, 2001). MUC1 is
proteolytically cleaved upon post-translational processing forming
two associated subunits at the cell surface (Parry et al, 2001).
For many years mucins have been implicated in the pathogen-
esis of cancer, especially adenocarcinomas (Apostolopoulos et al,
1999; Hu and Xing, 2003; Hollingsworth and Swanson, 2004). It is
postulated that tumour cells utilise mucins to remodel the local
microenvironment to promote tumour invasion, metastasis and
growth (Hollingsworth and Swanson, 2004). Overexpression of
MUC1 and the expression of aberrant forms of MUC1, typified by
the loss of apical distribution, have been reported in many
carcinomas (Zotter et al, 1988), in particular breast and ovarian
(Apostolopoulos et al, 1999; Hu and Xing, 2003). This aberrant
expression is a consequence of either the deregulation of the MUC1
gene itself or the genes encoding the enzymes, which modify the
MUC1 protein. Clatherin-mediated endocytosis of MUC1 is
stimulated two-fold and its intracellular trafficking and subcellular
distribution is altered as a probable consequence of the aberrant
glycosylation (Altschuler et al, 2000).
This differential glycolsylation allows MUC1 to be exploited as
a pan-carcinoma tumour-associated antigen with many B-cell
(Burchell et al, 1983) and T-cell (Jerome et al, 1991) epitopes. To
date, more than 50 monoclonal antibodies specific for the MUC1
protein have been described (Price et al, 1998). Most recognise
exposed epitopes within the 20-mer tandem repeat region
accessible due only to the differential glycosylation, thereby
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saffording these antibodies a degree of specificity for the cancer cell.
The most commonly recognised epitope is the hydrophilic
‘PDTRPAP’ sequence (Petrakou et al, 1998), which is predicted
to have a relatively unstructured conformation with a simple ‘fist-
like’ projection (Price et al, 1998).
The MUC1 specific murine monoclonal antibody HMFG-1
was raised against human milk fat globules, a rich source
of MUC1 and was subsequently shown to bind the exposed
tetra-peptide sequence ‘PDTR’ (Taylor-Papadimitriou et al,
1981). HMFG-1 and a humanised version of this antibody
HuHMFG-1, which has demonstrated similar specificity and
affinity for MUC1 (Verhoeyen et al, 1993), have both been
evaluated in clinical trials. Iodine-123-labelled HMFG-1 was
successfully used to detect MUC1 positive tumours in patients
with primary and metastatic lesions of ovarian, breast and
gastrointestinal cancer (Epenetos et al, 1982; Al-Yasi et al,
2002). A phase I/II clinical trial using yttrium-90 conjugated
murine HMFG-1 (R1549) showed promise in patients with ovarian
cancer (Hird et al, 1993). A follow-up phase III ‘SMART’ trial,
however, concluded that the antibody when given after standard
chemotherapy did not result in an increased survival benefit
compared to standard therapy alone (Seiden and Benigno,
2004). The unmodified humanised antibody (R1550) is currently
being developed as an immunotherapeutic for breast cancer
(Courtenay-Luck N, pers. comm.; http://www.antisoma.com/
products/R1550_Therex.asp) supported by evidence that this
antibody can elicit a strong antibody directed cellular cytotoxicity
response (Snijdewint et al, 2001).
As yet the potential of MUC1 as a tumour-associated antigen
that internalises has not been widely evaluated with respect to
the delivery of chemotherapeutic agents or toxins. The route and
kinetics of HuHMFG-1 internalisation are unknown and are
critical for the successful delivery of cytotoxic agents, which exert
their action in intracellular compartments. Addressing these issues
we constructed the single-chain Fv (scFv) and Fab recombinant
antibody fragments of HuHMFG-1 and assessed stability, affinity
and internalisation characteristics alongside the parent antibody.
The scFv was found to be insoluble and unstable and required
a stabilising mutation (Krauss et al, 2004). This is the first
report delineating the internalisation pathway of the clinically
tested HuHMFG-1 antibody with respect to antigen binding
and intracellular trafficking. Furthermore, surface plasmon
resonance (SPR)-measured binding data for the Fab and parent
antibody provide a fuller insight into the previously unchar-
acterised binding kinetics and affinity profiles of these antibodies
and is discussed in relation to the observed internalisation
characteristics.
MATERIALS AND METHODS
Materials
Humanised HMFG-1 monoclonal antibody was of clinical grade
purity and supplied by Antisoma Research Ltd, UK. Proteolytically
derived HuHMFG-1 Fab was prepared using a Pierce Fab
preparation kit following the manufacturer’s instructions. Anti-
HIS antibody was from Qiagen, Crawley, UK, Transferrin-Alexa
Fluor 594 was from Molecular Probes (Invitrogen, Paisley, UK).
Anti-mouse and anti-human-peroxidase and FITC conjugates
were from Sigma, Dorset, UK. pET20b vector and Escherichia coli
BL21(DE3) pLysE strains were from Novagen, Nottingham. A
fusion protein consisting of glutathione-s-transferase and one
MUC1 tandem repeat was a kind gift from Dr R Verma (Antisoma
Research Ltd, UK). The 60-mer MUC1 peptide containing three
tandem repeats (Henderikx et al, 2002) was a kind gift from Dr P
Henderikx (Dyax SA, Belgium). Anti-c-myc monoclonal antibody
9E10 was a kind gift from Professor N Lemoine (CRUK, London).
Plasmids pAS1 and pAS2 were kind gifts from Dr R Young
(Antisoma Research Ltd, UK).
Cell culture
The human tumour cell lines MCF-7, SKOV-3 and COS-7 were
obtained from the European Collection of Cell Cultures (ECACC)
and maintained in Eagle’s modified essential medium (EMEM)
with 10% foetal calf serum (FCS), McCoys medium with 15% FCS
and Dulbecco’s modified essential medium (DMEM) with 10% FCS
respectively. All cells were cultured in 75cm
2 flasks and passaged
at 70–90% confluency.
Construction of the HuHMFG-1 Fab expression vector
The VH-CH1 domain of the HuHMFG-1 Fab was PCR amplified
from plasmid pAS2 using the primers VHCH-N (50 CGCCT
CCATGGCAATCGATCAGG TGCAGCTGGGTGCAG 30)a n dV H C H - C
(50 GGCGCGCGGCCCGCATCGATAGCAACTTTCTTGTCCA CCTT
30), and ligated into the NcoI and NotI restriction sites of
pET20bþ. This clone was called pET20bHMFG1-H. The VL-CL
domain was PCR amplified from pAS1 using the primers VLCL-N
(50 TCC GCCTCCATGGCCGACATCCAGATGACCCAGAGC 30)
and VLCL-C (50 GGAGGCGTCGACCTAATTC AGATCCTCTTCTG
AGATGAGTTTTTGTTCACTCTCTCCCCTGTTGAA 30) and ligated
into the NcoI and SalI restriction sites of pET20bþ. This clone was
called pET20HMFG1-L. The Bpu11021I and NcoI restriction sites
were removed from the CL and VL domains, respectively, by silent
site-directed mutagenesis. Following this mutagenesis, the whole
expression cassette of pET20bHMFG1-L was PCR amplified using
primers VLCL-N2 (50 GCTCGCTAGCTGAGCAATTTTGTTTAACT
TTAAGAAGG 30) and VLCL-C2 (50 CGAGCGATGCTCAGCGTC
GAGCTAATTCAGATCCTCTTCTGA 30) and ligated into the
Bpu11021I restriction site of pET20bHMFG1-H, which is located
30 to the heavy chain gene. The integrity of the resulting HuHMFG-
1 Fab expression vector, called pETHuHMFG1, was confirmed by
restriction digest analysis and DNA sequencing. This clone
comprised of the Fab heavy chain (VH-CH1) with a C-terminal
hexa-histidine tag, the light chain (VL-CL) with a C-terminal c-
myc tag, with both chains preceded by a pel B secretion signal and
a ribosome binding site, and the whole construct under the control
of a single T7 promoter (Figure 1).
Expression and purification of the HuHMFG-1 Fab
Soluble HuHMFG-1 Fab was expressed in 1l cultures of E. coli
BL21 (DE3) pLysE (Studier, 1991), grown in 2TY media with
100mgml
 1 ampicillin and 25mgml
 1 chloramphenical at 371C
and induced with 0.1mM IPTG for 16h at 301C. The culture was
then centrifuged and the clarified supernatant was filtered
(0.2mm), concentrated 10-fold, dialysed into PBS/1 M NaCl and
subsequently purified by immobilised metal affinity chromato-
graphy (IMAC) on chelated cobalt sepharose (Talon
s, Clontech,
Oxford, UK). Further purification was achieved by size exclusion
chromatography using a Superdex-75 10/300 column equilibrated
in PBS. The protein eluted at its predicted native molecular weight
of 50kDa (data not shown) and SDS–PAGE/Western blot analysis
indicated that the purified protein contained both Fab chains with
the expected molecular weight (Figure 2).
Construction and expression of the HuHMFG-1 scFv gene
The gene encoding the HuHMFG-1 scFv was constructed by PCR
amplification and sequential cloning of the VH and VL antibody
domains from the pAS2 and pAS1 vectors, respectively, as
previously described (Krauss et al, 2004). Bacterial expression
resulted predominantly in inclusion body formation. Functional
scFv could be obtained from periplasmic preparations (Krauss
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set al, 2004), but higher yields of similarly functional scFv could be
obtained from refolding experiments (Deonarain et al, 1997) and
subsequent IMAC purification yielding pure protein as analysed by
SDS–PAGE and Western blot (Figure 2).
Antigen and fixed cell ELISAs
Micotitre plates (96-well) were either coated overnight with
5mgml
 1 of GST-MUC1 in PBS at 41C, or seeded with
approximately 10
6 cells/well, grown overnight and fixed with 2%
paraformaldehyde for 30min. Following the addition of
50mlwell
 1 of serially diluted purified antibody or appropriate
control samples in PBS/2% skimmed milk powder (Marvel
s),
binding was detected using mouse anti-His (scFv or Fab heavy
chain) or mouse anti-c-myc (Fab light chain) followed by an anti-
mouse peroxidase conjugate. Goat anti-human Fab-specific
peroxidase conjugate antibody was also used to detect the binding
of the Fab and whole HuHMFG-1 antibody for direct comparisons.
Each antibody incubation step was followed by three PBS/0.1%
Tween-20 washes and three PBS washes. All ELISAs were
developed with o-phenyldiamine (OPD) substrate. In the thermal
stability studies, antigen ELISAs were carried out after a 10-min
incubation in PBS at various temperatures.
Flow cytometric analyses
SKOV-3 or COS-7 cells were harvested from 75cm
2 flasks by
washing with sterile PBS and dissociation with Trypsin/EDTA.
Cells were washed twice in ice-cold DMEM/2% FCS and 10
6 cells
resuspended in 10–100mgml
 1 of primary antibody in a volume
of 0.2ml for 1h at 41C. Binding was detected using either 5mgml
 1
anti-human Fab specific FITC- (HuHMFG1 IgG and Fab) or
5mgml
 1 mouse anti-His FITC- (scFv) conjugates in 0.2ml for 1h
at 41C. Each antibody incubation step was followed by the
centrifuging (2min at 600g) and resuspention of the cells three
times in ice-cold PBS/2% FCS. Samples were analysed using a
3-colour Becton Dickinson FACSort machine at a single laser
excitation wavelength of 460–500nm. Data were analysed using
CellQuest software.
BIACore SPR binding kinetics
Studies were conducted using a BIACore 3000 (BIACore AB,
Upsala, Sweden) with version 4.0 control software. Carboxy-
Methyl Dextran (CM5) sensor chips were coated with approxi-
mately 1000 or 3000 response units (RU) of GST-MUC1 peptide on
the test flow cells, and either approximately 800 or 2400 RU of free
GST on the negative control flow cells. Standard amine coupling
methodology was used. Streptavidin (SA) sensor chips were coated
with approximately 150RU of nonspecific biotinylated peptide
(17-mer) ‘NH2-CYWFSRSGKAWADADNY-COOH’ on negative
control flow cells and approximately 50RU of biotinylated
MUC1 60-mer peptide ‘NH2-(VTSAPDTRPAPGSTA PPAHG)3-
COOH on test flow cells. Wizard-driven kinetic binding
DIQ....GEC..myc
AALEH6 MK...MA
NcoI SalI NcoI SalI
NcoI NotI
NcoI NotI NcoI SalI Bpu1102 I Bpu1102 I 
QVQ..........KKV
DIQ....GEC..myc
QVQ..........KKVA MK...MA
MK...MA
DIQ....GEC..myc
pAS1
pAS2
pT7 RBS
RBS pT7 RBS
VL-CL HuHMFG-1 pel B  VL-CL HuHMFG-1 myc tag
pel B VL-CL HuHMFG-1 myc tag pel B VH-CH HuHMFG-1 His-6 tag
T7 Term
PCR
PCR
pET20b
pET20b
PCR
pETHuHMFG1
Figure 1 Construction scheme for the HuHMFG-1 Fab. Plasmids pAS1 and pAS2 containing the light chain and heavy chain of the HuHMFG-1
immunoglobulin were used as templates to PCR amplify the fragments for Fab construction. These were cloned into pET20bþ individually and NcoI/SalI and
NcoI/NotI subgenes respectively. Then, the whole expression cassette for the light chain was amplified and cloned into the Bpu1102I site of the pET vector to
form the pETHuHMFG1 expression vector.
A
B
123456
a bc
Figure 2 Expression and purification of the HuHMFG-1 Fab and scFv.
(A) The Fab was isolated by IMAC from concentrated supernatant (lane 2)
to yield pure protein with both chains intact (lane 3). The scFv expressed
insolubly (lane 4), recovered as insoluble inclusion bodies (lane 5) and
purified after refolding (lane 6). Molecular weight markers are shown in lane
1 (116, 66, 45, 35, 25, 18, 14kDa). (B) Anti-c-myc Western blot analysis
detects the Fab light chain (a), Anti-His-6 blotting detects the Fab heavy
chain (b) and scFv (c). This shows that all the antibody fragments are full-
length proteins.
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sexperiments, set at a flow rate of 30mlmin
 1 to minimise rebinding
and mass transfer effects, were run in PBS containing 0.05%
Tween-20. Antibody samples serially diluted in running buffer
were tested in duplicate with the final data sets collated from two
separate experiments. Sensogram data were analysed using the
BIA-evaluation software version 3.1 with affinity and avidity
binding constants determined using either Langmuir 1:1, bivalent
or steady-state binding models. Automated ‘global’ curve fitting of
data sets typically yielded w
2 values between 5 and 20.
Confocal immunofluorescent microscopy
SKOV-3 cells were seeded onto 13mm coverslips and grown to
80% confluency. The cells were washed twice for 10min at room
temperature with Leibovitz medium (L-15) supplemented with
0.2% BSA and 0.1mgml
 1 iron nitrate (to eliminate any growth
factors and excess transferring) and chilled to 41C. Transferrin-
Alexa Fluor 594 and the appropriate HuHMFG-1 antibody (5–
100mgml
 1) were applied to the cells at 41C for 30min. Three
washes with chilled L-15/0.2% BSA/0.1mg/ml iron nitrate were
conducted before incubation at 371C for various time points,
followed by fixation for 15min in 4% paraformaldehyde. Cells
were permeablised and blocked with 0.1% saponin/1% BSA/PBS
for 1h at room temperature before applying 5mgml
 1 anti-human
Fab-specific FITC (diluted in 0.1% saponin/1% BSA/PBS) for a
further 60min. This was followed by six 10min washes with
0.1% saponin/1% BSA/PBS and mounting of the coverslips onto
microscope slides, using Vectashield
TM (Vectalabs) mounting
medium and nail varnish. Slides were viewed on a Zeiss LSM
510 laser-scanning confocal microscope. The LSM 510 software
was used for image processing. The Volocity
s programme was
used to re-construct 3D images and movies from image slices.
RESULTS
Production of the HuHMFG-1 scFv and Fab
The bacterial expression of HuHMFG-1 scFv led predominantly to
insoluble inclusion body formation with limited yields of soluble,
functional protein obtained following refolding and IMAC
purification (Figure 2). In contrast, expression and purification
of the HuHMFG-1 Fab fragment yielded soluble protein at 4mgl
 1
of bacterial culture (Figure 2). Furthermore, the nonproblematic
soluble expression of the individual heavy (VH-CH1) and light
(VL-CL) chains from pET20bHuHMFG1-H and pET20b-
HuHMFG1-L, respectively, suggested that the constant domains
were the source of the increased stability and solubility of the Fab
in comparison with the scFv (data not shown). Fab stability on
storage (data not shown) or after prolonged heat treatment, at a
range of temperatures was comparable to the parent IgG (Figure 3).
The scFv, however, exhibited significantly poorer stability
compared to other antibody species with an 80% decrease in
binding at 601C (Figure 3). Fab antibody was also made from the
proteolysis of whole HuHMFG-1 IgG for comparison.
Cell and antigen binding assays
Both the recombinant HuHMFG-1 Fab and scFv showed specific
antigen binding by ELISA against the GST-MUC1 peptide,
demonstrating retention of the antigen specificity of the parent
IgG. Additionally, no significant binding was detected against a
range of nonspecific protein antigens, including BSA, lysozyme
and unconjugated GST. The binding affinity was low with
saturating binding not being achieved (data not shown). Com-
parative ELISAs against fixed MCF-7 cells (Figure 4), which
express the native MUC1 tumour antigen, gave reasonably high
apparent affinity values (IgG – 3.9 10
 9 M, recombinant Fab –
3.3 10
 8 M, proteolytic Fab – 3.2 10
 8 M (not shown) and scFv –
3.7 10
 8 M), which were at least 10-fold (and approaching
100-fold) better than the peptide binding for each antibody
species. Analysis by flow cytometry using antigen positive
(SKOV-3) and antigen negative (COS-7) live cells demonstrated
further the specificity of these recombinant antibodies. Significant
shifts in fluorescence intensity were observed with the antigen
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Figure 3 Thermostability profile of HuHMFG-1 antibodies. Antibody
samples were incubated at the temperatures indicated and the percentage
binding activity (by ELISA) was plotted. IgG (closed squares), Fab (closed
diamonds) and scFv (closed triangles). The Fab is seen to be at least 101C
more thermo-stable than the scFv fragment.
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Figure 4 HuHMFG-1 cell ELISAs. Cell ELISAs of the various HuHMFG1
antibodies on antigen-positive cells (MCF-7) and -negative cells (Cos-7).
For binding to MCF-7 tumour cells, IgG (closed circles), Fab (closed
triangles) and scFv (closed squares). For binding to Cos-7 cells, IgG (open
circles), Fab (open squares) and scFv (open triangles). Binding curves were
fit to a sigmoidal 4-logistic equation (SigmaPlot) and mid-points of binding
(equivalent to the apparent equilibrium dissociation constants, KDs)
determined. Apparent KDs determined from these are
IgG¼3.970.4 10
 9 M, recombinant Fab¼3.3470.09 10
 8 M, proteo-
lyic Fab¼3.1670.3 10
 8 M (not shown) and scFv¼3.6570.2 10
 8 M.
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spositive cell line only for each of the three antibody species,
recombinant scFv, recombinant and proteolytically derived Fab
and parent IgG (Figure 5). Compared to the FITC-treated cell
control (mean fluorescence¼4.49U), scFv binding resulted in a
shift to 23.3U, whereas the proteolytic Fab resulted in a shift to
34.1U, recombinant Fab resulted in a shift 29.5U and the whole
IgG resulted in a shift 275.6U.
SPR kinetic binding studies
A more detailed analysis of the binding kinetics of the HuHMFG-1
Fab and parent IgG was obtained using SPR with the BIACore
3000. The unmodified scFv described in this study was not
analysed as it is an unlikely candidate for further development due
to the afore-mentioned solubility and stability limitations during
recombinant production. BIACore SPR curves are shown for the
whole antibody against a GST-MUC1 fusion protein (Figure 6A
and B) and a MUC1 peptide with three tandem repeats (Figure 6E
and F). Both showed similar shaped curves with association rates
(ka) values ranging between 1.76 10
5 and 4.2 10
5M
 1s
 1 and
dissociation rates (kd) values ranging from 0.022 and 0.095s
 1
depending on the curve fitting model used (Table 1). As the parent
IgG is bivalent a 1:1 binding model gave a poor fit and therefore
resulted only in an approximation of the kinetic constants. A mass
transfer correction did not improve the fit (data not shown). The
bivalent model of binding was, as expected, more appropriate for
the analysis of the IgG kinetics as indicated by the lower w
2 value
and the derived ka1 and kd1 values compare well to those derived
from the 1:1 fit (Table 1). A steady-state approximation of the
KD value for the GST-MUC1 (Figure 6C) and 60-mer peptide
(Figure 6D) also agrees well with the estimates from the other
models. The KDs ranged from 1.01 10
 7 to 4.9 10
 7 M (Table 1).
The recombinant Fab fragment gave binding curves indicative of
lower association and dissociation rates compared to the parent
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Figure 5 Flow cytometric analyses of live cell binding. (A and B) Binding to antigen-negative COS-7 cells and (C and D) binding to antigen-positive
SKOV-3 cells. (A) Bold line¼cells/detection antibodies only, thin line¼HuHMFG-1 scFv, dashed line¼proteolytically-derived Fab. (B) Bold line¼cells/
detection antibodies only, thin line¼recombinant Fab, dashed line¼whole HMFG-1 IgG. (C) Bold line¼cells/detection antibodies only (geometric mean of
fluorescence intensity 4.7), thin line¼proteolytically-derived Fab (34.1), dashed line¼HuHMFG-1 scFv (23.3). (D) Bold line¼cells/detection antibodies
only (4.7), thin line¼recombinant Fab (29.5), dashed line¼whole HMFG-1 IgG (275.6). The Fab species show similar binding with the whole IgG binding
live cells more effectively.
Characterisation and internalisation of HuHMFG-1
LM Pericleous et al
1261
British Journal of Cancer (2005) 93(11), 1257–1266 & 2005 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sIgG with ka values of 865 and 5650 M
 1s
 1 and kd values of 0.031
and 0.058s
 1 respectively for the GST-MUC1 fusion protein
(Figure 6G and the 60-mer tandem repeat (Figure 6F) (Table 1).
For comparison, the proteolytically derived HuHMFG-1 Fab gave
very similar kinetic values to the recombinant molecule (Table 1).
Confocal microscopy of HuHMFG-1 internalisation
The internalisation and intracellular trafficking of the HuHMFG-1
antibody/MUC1 complex was analysed by confocal immunofluor-
escence microscopy. Initially, data from a pilot time course
experiment using the HuHMFG-1 IgG were used to select a window
within which the relevant intracellular trafficking data could be
acquired. Time points of 0, 5, 15 and 30min were subsequently
selected for further analysis. The majority of the HuHMFG-1 IgG
was internalised rapidly within 15 to 30min (Figure 7A), the
intracellular staining was punctate and characteristic of early
endosomal localisation. This was confirmed with additional
colocalisation studies following the internalisation of Alexa
Fluor-594 labelled transferrin via the transferrin receptor, which
is known to cycle through early endosomes. Significant colocalisa-
tion with the labelled transferrin was observed with both the
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Figure 6 BIAcore surface plasmon resonance kinetic analyses. Sensogram plots for IgG and recombinant Fab binding experiments on immobilised Gst-
MUC1 peptide and 60-mer biotinylated peptide. Approximately 3min of association and 3min of dissociation are shown. IgG binding curves for the Gst-
MUC1 antigen fit to (A) bivalent analyte model and (B) 1:1 binding model. Steady-state binding curves for Gst-MUC1 (C) and 60-mer peptide (D). IgG
binding curves for the 60-mer antigen fit to a bivalent analyte model (E) and a 1:1 binding model (F). Fab binding curves, fit to a 1:1 model on Gst-MUC1
antigen (G) and 60-mer peptide (H). The proteolytically derived Fab gave similar binding curves (data not shown). Derived constants for all species are
shown in Table 1.
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pathway (Figure 7B). The lower affinity of the Fab or its reduced
valency, however, resulted in less endosomal localisation com-
pared to the IgG. Coefficients (Figure 7, legend) for transferrin and
antibody colocalisation were derived from the immunofluores-
cence data, showing high correlation with the whole IgG, peaking
at 15min. This peak time of colocalisation is also observed with the
Fab fragment but with a lower absolute correlation value. Studies
with markers for the endoplasmic reticulum and lysozomes
showed no significant colocalisation (data not shown) and no
binding or internalisation was seen with the COS-7 MUC1 negative
cell line (data not shown). A clearer visualisation of the
internalised HuHMFG-1 IgG colocalising with the endosomal
marker can be seen in the gallery of images, which shows the cells
after 15min (maximal colocalisation) sliced through the Z-plane
(supplementary Figure 1). These images were reconstructed into
a three-dimensional model, which is shown rotating 3601 in a
Quicktime
TM movie (supplementary Figure 2). The cells are seen as
flattened onto the slide surface, but the depth and internal features
can be seen.
DISCUSSION
This study described the construction and characterisation of the
monovalent scFv and Fab fragments of the anti-MUC1 human
immunoglobulin HuHMFG-1. Smaller antibody fragments are
attractive due to potentially improved tumour penetration and
rapid pharmacokinetic properties compared with the IgG format
and also offer greater scope and facility for the production of
recombinantly derived fusion proteins. Although antigen specifi-
city is generally retained following this type of reformatting the
loss of bivalency and the absence of the Fc domain necessitates a
detailed in vitro analysis prior to any in vivo experiments. The
analysis of both the HuHMFG-1 scFv and Fab described here
benefited from direct comparison with the whole immunoglobulin,
which has already undergone extensive clinical testing (Epenetos
et al, 1982; Seiden and Benigno, 2004).
The poor solubility and stability of the HuHMFG-1 scFv are
features that have been commonly observed with other hybridoma-
derived scFvs, and further studies have shown that a specific
mutation is required to resolve these shortcomings (Krauss et al,
2004). Despite this, work here and previous research (Deonarain
et al, 1997) has shown that sufficient yields can be obtained from
refolding inclusion bodies. The improved solubility and stability
of the HuHMFG-1 Fab in comparison with the scFv (thereby
removing the need for refolding) was therefore predominantly
attributed to the presence of the constant domains. Fab fragments
often demonstrate preferred in vivo pharmacokinetics when
directly compared with scFvs as a result of the increase in
molecular weight, with many reports describing the suitability of
this antibody format for therapeutic applications such as radio-
immunotherapy (Alberici et al, 1988) or drug delivery (Casey et al,
2002).
Previous studies using Scatchard analysis determined the
equilibrium dissociation constants (KD) of the proteolytically
derived human Fab fragment as 2.7 10
 7 M respectively (Davies
et al, 1994). We were unable to accurately determine the affinities
of the Fab or scFv by ELISA, but the BIACore SPR analysis gave
significantly lower affinity values. It has been observed by others
that the HuHMFG-1 IgG has a low affinity for artificial peptide
antigens and values for the IgG have been determined to be about
1 10
 7 M (Karanikas et al, 1998) agreeing with our observations.
The better KD values for the antibody species on fixed cells
suggests that the antigen, when expressed on the cell surface, exists
in a more favourable conformation than that of the GST-MUC1
fusion protein or 60-mer peptide absorbed to a plastic surface or
immobilised onto a Carboxy-Methyl dextran chip. The KD values
for monomeric species of HuHMFG-1 on MCF-7 cells was 33–
36nM, three-fold better than the 113nM observed for the equivalent
scFv in the Krauss et al (2004) study. This could be accounted for
by differences the level or quality of tumour-associated MUC1
expression on the cells used but supports the relevance of native
antigen. The likelihood of crosslinking of the bivalent IgG is
potentially increased due to the high-density antigen expression
and the multivalent tandem repeat structure of native MUC1. Also,
the proposed ‘fist-like’ projection of the tandem repeat loop, which
is probably only apparent with cell-tethered MUC1 may promote
a higher affinity interaction with the antibody. The HuHMFG-1
antibody was originally raised against native tumour-associated
MUC1 and not an artificial peptide and the subtle difference in
specificity and affinity is apparent here. Binding analysis on
Table 1 Surface plasmon resonance kinetic analyses of antibody binding
Gst-MUC1 fusion protein (1-repeat) 60-mer MUC1 peptide (3-repeats)
1:1 Bivalent Steady state 1:1 Bivalent Steady state
HuHMFG-1 IgG
ka (M
 1s
 1) 4.2 10
5 1.76 10
5 NA 4.1 10
5 2 10
5 NA
ka (s
 1) 0.049 0.086 NA 0.022 0.095 NA
KD (M) 1.18 10
 7 4.9 10
 7 1.3 10
 7 1.83 10
 7 1.68 10
 7 1.01 10
 7
Fit (w
2)3 0 6 8 5 0 5 9
HuHMFG-1 Fab-(recomb.)
ka (M
 1s
 1) 865 NA ND 5650 NA ND
kd (s
 1) 0.031 NA ND 0.058 NA ND
KD (M) 3.6 10
 5 NA ND 1 10
 5 NA ND
Fit (w
2)1 7N A N D 1 2 N AN D
HuHMFG-1 Fab (prot.)
ka (M
 1s
 1) 1310 NA ND 5727 NA ND
kd (s
 1) 0.038 NA ND 0.063 NA ND
KD (M) 2.9 10
 5 NA ND 1.1 10
 5 NA ND
Fit (w
2)1 9N A N D 1 5 N AN D
Association and dissociation rate constants are shown for the binding of HuHMFG-1 IgG and Fab, on Gst-MUC1 and 60-mer MUC1 peptides. Each binding experiment was fit to
a 1:1 Langmuir binding model and bivalent analyte model (BIAevaluation 3.01) and the degree of fit is indicated by the w
2 value. The derived equilibrium dissociation constant is
shown as well as a determination by steady-state analysis. NA¼not applicable, ND¼not determined.
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(Backstrom et al 2003) would shed more light on this problem.
By BIACore SPR (below), the affinity values obtained for the
recombinant Fab was approximately 50- to 300-fold lower than the
human IgG mirroring the trend of the ELISAs.
Live cells FACS analyses showed that the various HuHMFG-1
species were specific for MUC1 antigen-expressing cells. The
fluorescence intensity shifts were similar for the monovalent
fragments with the whole IgG showing an almost 10-fold further
shift in fluorescence, supporting the cell ELISA observations.
The SPR studies gave a more detailed insight into the binding
kinetics of these antibodies with the IgG unusually benefiting
from an enhanced association rate compared to the Fab, but with
both formats exhibiting similar dissociation rates. It is normally
expected that a bivalent antibody species will exhibit a higher
overall affinity value due to a slower dissociation rate in
comparison with a monovalent species (Nielsen et al, 2000).
Although the kinetic data for the IgG resulted in a poor fit when
analysed using the 1:1 interaction model, the KD value
(1.18 10
 7 M) was similar to that obtained from the bivalent
analyte model (4.9 10
 7 M), which gave a closer fit, and also
steady-state analysis (1.3 10
 7 M). These results, obtained using
the GST-MUC1 fusion protein, were similar to those using the
60-mer MUC1 peptide comprised of three tandem repeats. As
expected, the kinetic analysis of the monovalent Fab resulted in a
good fit using the standard 1:1 model on both the GST-MUC1 and
the 60-mer MUC1 peptide with an affinity value approximately
50—to 300-fold lower than that of the IgG. There was practically
no difference between the proteolytically derived and recombinant
Fab in terms of kinetic binding constants. Compared to other well-
characterised antibodies the calculated dissociation rate constants
of both the HuHMFG-1 Fab and IgG are rapid (Price et al, 1998;
Nielsen et al, 2000). This was measured on synthetic antigen and
could be a major limitation as the overall affinity for native antigen
was significantly higher. Despite this, it is likely that antibody
dissociation rate is not such a critical factor when targeting rapidly
internalised antigens such as MUC1. This is supported by good
IC50s for tumour cell killing with ribonuclease-based immuno-
fusions in vitro (Krauss et al, 2004) and immuno-conjugates in
vivo (Courtenay-Luck et al, 2003). The limitations of using
synthetic antigens are apparent here and consistent with past
observations: the Campath-1H monoclonal antibody (Alemtuzu-
mab), now approved for the treatment of chronic lymphocytic
leukaemia (Keating et al, 2002), did not bind to its synthetic
peptide antigen, but did bind to native deglycosylated or
proteolysed peptide (Hale, 1995).
Confocal immunofluorescent microscopy was used to charac-
terise the internalisation of both the HuHMFG-1 Fab and IgG
antibody–antigen complexes using live MUC1 expressing cells.
Previous studies have indicated that the rate of antibody-MUC1
internalisation may be dependent on the specific epitope that the
antibody recognises, with an ‘RPAP’-specific antibody internali-
sing more rapidly than an ‘APDTR’-specific antibody (Pietersz
et al, 1997). However, the results from our fluorescent microscopy
show most of the ‘PDTR’-specific HuHMFG-1 antibody rapidly
internalises within 15min, again demonstrating the importance of
fine specificity in internalisation. The lower affinity value of the
Fab resulted in less total antibody internalisation but at a
comparable rate to the IgG. The MUC1 antigen has been reported
to recycle at a rate of 0.9%/min (Altschuler et al, 2000), which is
slower than would allow such rapid HuHMFG-1 accumulation.
However, we are measuring HuHMFG-1 localisation and not
HuHMFG-1 IgG – 0 min
HuHMFG-1 IgG – 15 min
HuHMFG-1 IgG – 5 min
HuHMFG-1 IgG – 30 min
A
HuHMFG-1 Fab – 0 min
HuHMFG-1 Fab – 15 min
HuHMFG-1 Fab – 5 min
HuHMFG-1 Fab – 30 min
B
Figure 7 Confocal immunofluorescent binding of HuHMFG-1 (A) IgG
and (B) Fab to MCF-7 breast cancer cells. (A) Time course of binding for
the IgG detected with anti-Fab FITC (green – upper right panel of each
time point). The endosomal compartment of the same cells is visualised
with transferrin-Alexa Fluor 594 (red – upper left panel of each time point).
The transmission image is shown for each cell (lower left panel of each time
point) and the superimposed image is shown for each time point (lower
right panel for each time point). (B) The same experiment represented the
same way for the Fab. The Zeiss LSM 510 software calculates fluorescence
colocalisation with a coefficient of 1 meaning completely overlapping
signals. For the green and red signals, these values are seen to increase with
time, peaking at 15min where the colocalisation is maximal. Higher
colocalisation is seen for the whole IgG. The values are as follows: IgG:
0min¼0.16, 5min¼0.34, 15min¼0.79, 30min¼0.55. Fab: 0min¼0.12,
5min¼0.22, 15min¼0.42, 30min¼0.23).
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crosslinking may increase MUC1 turnover as is sometimes seen for
other antigens. Colocalisation studies of these antibodies with
additional endosomal staining (Transferrin-Alexa Fluor 594)
showed that the HuHMFG-1 IgG trafficks to early endosomes with
increasing colocalisation correlation coefficients peaking at 15min.
Colocalisation and internalisation is clearly seen in the Z-plane
images and 3D reconstruction in all parts of the cell. At 30min
some of the HuHMFG-1 is clearly lost to degradation leading to a
drop in the correlation coefficients. The Fab fragment exhibited an
overall lower degree of colocalisation, presumably related to its
significantly lower association rate as determined by SPR, but
peaked at the same time point as the IgG.
The C-terminal tail of MUC1 has a number of potential
endosomal cycling/sorting motifs, based on the ‘YXXPhi’ sequence
(reviewed in Bonifacino and Traub, 2003). These motifs are
correctly positioned in MUC1 to interact with the AP adaptor
proteins in the clatherin complexes (Bonifacino and Traub, 2003).
These sequences are ‘YGQL’, ‘YEKV’ and ‘YPTY’, the latter being
closest to the consensus. These sequences exhibit similarity with
the known motif found in the transferrin receptor ‘YTRF’
(Bonifacino and Traub, 2003). This may explain the similar
intracellular localisation patterns observed with the immunofluor-
escence microscopy. Whereas the transferrin receptor does not
play a signalling role upon endosomal cycling, there is accumula-
ting evidence that MUC1 does have some signal transduction
function. This is supported by the fact that some of these sorting
motifs are within phosphorylated signalling motifs (Zrihan-Licht
et al, 1994; Wang et al, 2003).
In conclusion, we have determined the affinities and kinetic
binding constants for monovalent and bivalent human HMFG-1
antibodies and shown how this related to cell binding and route of
internalisation. A rapid dissociation rate was determined but this
has not adversely affected therapeutic strategies such as targeted
apoptosis, where cytotoxic enzymes are delivered to the cytosol of
tumour cells.
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